Author details
Author Christiaan Marais |
Available item(s) by this author (2)
Add the result to your basket Make a suggestion Refine your search Apply to external sourcesKosteneffectiviteit van vaccinatie tegen windpokken bij kinderen en tegen zona bij ouderen in België. / J Bilcke / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
ISSN : D/2010/10.273/102 : € 0,00
Studie n° 2009-10
2011-01-24 (2nd print; 1st print: 2011-01-19<br>)
Languages : English (eng) Dutch (nla)
Descriptors: Indexation
2009-10 ; Chickenpox Vaccine ; Cost-Benefit Analysis ; Herpes Zoster Vaccine ; measles, mumps, rubella, varicella vaccine [Substance Name] ; R151
Classification
WC 571 Herpesviridae infections (General or not elsewhere classified)Abstract: Een vaccinatieprogramma van kinderen tegen windpokken, en van ouderen tegen zona, wat zouden de kosten en baten hiervan zijn? Deze vraag onderzocht het Centrum voor Gezondheidseconomie en Modellering van Infectieziekten (Universiteit Antwerpen) in opdracht van het Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Een vaccinatieprogramma tegen windpokken kan best pas opgestart worden als men zeker is dat daardoor het aantal gevallen van zona niet tegelijkertijd te sterk toeneemt. Daarvoor moeten de resultaten in een aantal landen, die reeds met vaccinatie zijn gestart, worden afgewacht. Voor vaccinatie tegen zona van zestig plussers zijn er te weinig betrouwbare gegevens beschikbaar om de baten eenduidig in te schatten. Contents note: 1 GENERAL BACKGROUND 3 -- 1.1 CLINICAL MANIFESTATIONS 3 -- 1.2 TRANSMISSION 3 -- 2 DATA SOURCES AND INTERMEDIARY DATA ANALYSES 5 -- 2.1 DATA SOURCES 5 -- 2.1.1 MCD-HBD 5 -- 2.1.2 Carenet 5 -- 2.1.3 Surveys amongst NCSF members 6 -- 2.1.4 Child & Family survey 7 -- 2.1.5 Social contact patterns 7 -- 2.1.6 Serological surveys 7 -- 2.1.7 Flemish Agency for Care and Health 8 -- 2.1.8 Scientific Institute of Public Health (SIPH) 9 -- 2.1.9 Scott et al (2006) data 9 -- 2.1.10 Scientific literature 9 -- 2.2 HOSPITALISATIONS, PHYSICIAN CONSULTATIONS AND DEATHS DUE TO -- CHICKENPOX AND HERPES ZOSTER 10 -- 2.2.1 Hospitalisations due to CP and HZ 10 -- 2.2.2 Physician consultations due to CP and HZ 21 -- 2.2.3 Total number of people with CP and HZ 24 -- 2.2.4 Deaths due to CP and HZ 25 -- 2.2.5 Postherpetic neuralgia (PHN) 28 -- 2.2.6 HZ related burden-of-illness (BOI) 29 -- 2.3 COSTS RELATED TO CHICKENPOX AND HERPES ZOSTER 36 -- 2.3.1 Costs for people hospitalised for CP and HZ 36 -- 2.3.2 Cost for ambulatory care related to CP and HZ 42 -- 2.4 CP AND HZ RELATED LOSS IN QOL 48 -- 2.4.1 CP related loss in QoL 48 -- 2.4.2 HZ related loss in QoL 50 -- 2.5 BURDEN OF BREAKTHROUGH CP 52 -- 2.6 HZ IN IMMUNOCOMPETENT POPULATION 52 -- 2.7 USE OF ANTIVIRAL MEDICATION FOR HZ 54 -- 2.8 VACCINE RELATED CHARACTERISTICS 54 -- 2.8.1 Childhood VZV vaccination (“chickenpox” vaccination) 54 -- 2.8.2 Adult VZV booster vaccination (“herpes zoster” vaccination) 55 -- 3 COST-UTILITY ANALYSIS: METHODS 70 -- 3.1 VACCINATION OF ADULTS TO PREVENT HERPES ZOSTER 70 -- 3.1.1 Main outcome 70 -- 3.1.2 Mathematical model structure. 70 -- 3.1.3 Uncertainty and sensitivity analysis 71 -- 3.1.4 Overview tables of the estimated and assumed input parameters for the HZ model 72 -- 3.2 VACCINATION OF CHILDREN AGAINST PRIMARY VZV INFECTION 78 -- 3.2.1 Main outcome 78 -- 3.2.2 Mathematical model structure. 78 -- 3.2.3 Fitting to Belgian data 80 -- 3.2.4 Options for childhood VZV (CP) vaccination 82 -- 3.2.5 Overview tables of the estimated and assumed input parameters for the VZV model 83 -- 4 COST-UTILITY ANALYSIS: RESULTS 85 -- 4.1 VACCINATION AGAINST HZ: RESULTS. 85 -- 4.1.1 Clinical and economic impact of HZ vaccination 85 -- 4.1.2 Cost-utility of HZ vaccination 88 -- 4.2 PRIMARY VZV (CP) VACCINATION: RESULTS 93 -- 4.2.1 Impact of vaccination against CP (and HZ) assuming exogenous boosting 94 -- 4.2.2 Impact of vaccination against CP assuming no exogenous boosting 109 -- 5 DISCUSSION 113 -- 5.1 VACCINATION AGAINST HZ 113 -- 5.1.1 Comparison of our results with previous published CUA’s 116 -- 5.1.2 Strengths and weaknesses of our CUA of HZ booster vaccination in elderly compared -- to previously published CUA’s, with respect to: 117 -- 5.1.3 General conclusion 119 -- 5.2 VACCINATION AGAINST CP (AND HZ) 119 -- 5.2.1 Strengths and weaknesses of our CUA of VZV vaccination in children (and booster in adults) compared to previously published CUA’s 121 -- 6 APPENDICES 123 -- 7 REFERENCES 129 Link for e-copy: https://doi.org/10.57598/R151A Format of e-copy: PDF (2,9 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2326 Copies
Barcode Call number Media type Location Section Status No copy
ISSN : D/2010/10.273/103 : € 0,00
Etude n° 2009-10
2011-01-24 (2nd print; 1st print: 2011-01-19
Languages : English (eng) French (fre) Original Language : French (fre)
Descriptors: Indexation
2009-10 ; Chickenpox Vaccine ; Cost-Benefit Analysis ; Herpes Zoster Vaccine ; measles, mumps, rubella, varicella vaccine [Substance Name] ; R151
Classification
WC 571 Herpesviridae infections (General or not elsewhere classified)Abstract: Quels seraient les coûts et les bénéfices associés à des programmes de vaccination contre la varicelle chez les enfants et contre le zona chez les adultes ? Le Centre d’évaluation économique et de modélisation des maladies infectieuses de l’Université d’Anvers (CHERMID) a examiné ces questions pour le compte du Centre fédéral d’expertise des soins de santé (KCE). L’étude révèle qu’un programme de vaccination contre la varicelle n’est souhaitable que si l’on est certain qu’il n’engendrera pas d’augmentation trop importante du nombre de zonas. Les résultats, non encore disponibles, d’autres pays où la vaccination a déjà lieu devraient nous permettre d’en savoir plus. Les avantages de la vaccination des personnes âgées contre le zona ne sont pas clairs non plus à cause du manque actuel de données fiables. Contents note: 1 GENERAL BACKGROUND 3 -- 1.1 CLINICAL MANIFESTATIONS 3 -- 1.2 TRANSMISSION 3 -- 2 DATA SOURCES AND INTERMEDIARY DATA ANALYSES 5 -- 2.1 DATA SOURCES 5 -- 2.1.1 MCD-HBD 5 -- 2.1.2 Carenet 5 -- 2.1.3 Surveys amongst NCSF members 6 -- 2.1.4 Child & Family survey 7 -- 2.1.5 Social contact patterns 7 -- 2.1.6 Serological surveys 7 -- 2.1.7 Flemish Agency for Care and Health 8 -- 2.1.8 Scientific Institute of Public Health (SIPH) 9 -- 2.1.9 Scott et al (2006) data 9 -- 2.1.10 Scientific literature 9 -- 2.2 HOSPITALISATIONS, PHYSICIAN CONSULTATIONS AND DEATHS DUE TO -- CHICKENPOX AND HERPES ZOSTER 10 -- 2.2.1 Hospitalisations due to CP and HZ 10 -- 2.2.2 Physician consultations due to CP and HZ 21 -- 2.2.3 Total number of people with CP and HZ 24 -- 2.2.4 Deaths due to CP and HZ 25 -- 2.2.5 Postherpetic neuralgia (PHN) 28 -- 2.2.6 HZ related burden-of-illness (BOI) 29 -- 2.3 COSTS RELATED TO CHICKENPOX AND HERPES ZOSTER 36 -- 2.3.1 Costs for people hospitalised for CP and HZ 36 -- 2.3.2 Cost for ambulatory care related to CP and HZ 42 -- 2.4 CP AND HZ RELATED LOSS IN QOL 48 -- 2.4.1 CP related loss in QoL 48 -- 2.4.2 HZ related loss in QoL 50 -- 2.5 BURDEN OF BREAKTHROUGH CP 52 -- 2.6 HZ IN IMMUNOCOMPETENT POPULATION 52 -- 2.7 USE OF ANTIVIRAL MEDICATION FOR HZ 54 -- 2.8 VACCINE RELATED CHARACTERISTICS 54 -- 2.8.1 Childhood VZV vaccination (“chickenpox” vaccination) 54 -- 2.8.2 Adult VZV booster vaccination (“herpes zoster” vaccination) 55 -- 3 COST-UTILITY ANALYSIS: METHODS 70 -- 3.1 VACCINATION OF ADULTS TO PREVENT HERPES ZOSTER 70 -- 3.1.1 Main outcome 70 -- 3.1.2 Mathematical model structure. 70 -- 3.1.3 Uncertainty and sensitivity analysis 71 -- 3.1.4 Overview tables of the estimated and assumed input parameters for the HZ model 72 -- 3.2 VACCINATION OF CHILDREN AGAINST PRIMARY VZV INFECTION 78 -- 3.2.1 Main outcome 78 -- 3.2.2 Mathematical model structure. 78 -- 3.2.3 Fitting to Belgian data 80 -- 3.2.4 Options for childhood VZV (CP) vaccination 82 -- 3.2.5 Overview tables of the estimated and assumed input parameters for the VZV model 83 -- 4 COST-UTILITY ANALYSIS: RESULTS 85 -- 4.1 VACCINATION AGAINST HZ: RESULTS. 85 -- 4.1.1 Clinical and economic impact of HZ vaccination 85 -- 4.1.2 Cost-utility of HZ vaccination 88 -- 4.2 PRIMARY VZV (CP) VACCINATION: RESULTS 93 -- 4.2.1 Impact of vaccination against CP (and HZ) assuming exogenous boosting 94 -- 4.2.2 Impact of vaccination against CP assuming no exogenous boosting 109 -- 5 DISCUSSION 113 -- 5.1 VACCINATION AGAINST HZ 113 -- 5.1.1 Comparison of our results with previous published CUA’s 116 -- 5.1.2 Strengths and weaknesses of our CUA of HZ booster vaccination in elderly compared -- to previously published CUA’s, with respect to: 117 -- 5.1.3 General conclusion 119 -- 5.2 VACCINATION AGAINST CP (AND HZ) 119 -- 5.2.1 Strengths and weaknesses of our CUA of VZV vaccination in children (and booster in adults) compared to previously published CUA’s 121 -- 6 APPENDICES 123 -- 7 REFERENCES 129 Link for e-copy: http://doi.org/10.57598/R151B Format of e-copy: PDF (2,9 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2325 Copies
Barcode Call number Media type Location Section Status No copy Readers who borrowed this document also borrowed:
Science Library of Congress Gebruik van point-of care systemen bij patiënten met orale anticoagulatie Gailly, Jeannine Ecrire en santé publique Leguéré, Jean-Pierre Manuel pratique de bibliothéconomie Vanzieleghem, Eric Pratique de MySQL et PHP Rigaux, Philippe Social sciences Library of Congress Les publications électroniques Remize, Michel Logiciels libres en gestion de l'information Remize, Michel Office 2007 Shoup, Kate Licensing digital content Harris, Lesley Ellen Geneesmiddelen ter preventie van osteoporosische fracturen Roberfroid, Dominique
